Your browser doesn't support javascript.
loading
Population pharmacokinetic modeling to establish the role of P-glycoprotein on ciprofloxacin distribution to lung and prostate following intravenous and intratracheal administration to Wistar rats.
Zimmermann, Estevan Sonego; de Miranda Silva, Carolina; Neris, Camila; Torres, Bruna Gaelzer da Silva; Schmidt, Stephan; Dalla Costa, Teresa.
Afiliação
  • Zimmermann ES; Pharmaceutical Sciences Graduate Program, Federal University of Rio Grande do Sul, Porto Alegre, Brazil.
  • de Miranda Silva C; Center for Pharmacometrics & Systems Pharmacology, College of Pharmacy, University of Florida, Orlando, USA.
  • Neris C; Pharmaceutical Sciences Graduate Program, Federal University of Rio Grande do Sul, Porto Alegre, Brazil.
  • Torres BGDS; Pharmaceutical Sciences Graduate Program, Federal University of Rio Grande do Sul, Porto Alegre, Brazil.
  • Schmidt S; Center for Pharmacometrics & Systems Pharmacology, College of Pharmacy, University of Florida, Orlando, USA.
  • Dalla Costa T; Pharmaceutical Sciences Graduate Program, Federal University of Rio Grande do Sul, Porto Alegre, Brazil. Electronic address: dalla.costa@ufrgs.br.
Eur J Pharm Sci ; 127: 319-329, 2019 Jan 15.
Article em En | MEDLINE | ID: mdl-30423435
Ciprofloxacin (CIP) is indicated for clinical treatment of urinary and respiratory tract infections. Poor infection site penetration and consequent insufficient exposure to the antimicrobial agent may be the reason for some therapeutic failures. Ciprofloxacin is reported as a substrate for efflux transporters, such as P-glycoprotein, which could be related to the presence of sub-therapeutic drug concentration at the infection site. In the present work we evaluated CIP pharmacokinetics (PK) in plasma and lung and prostate tissues of Wistar rats after intravenous (i.v.) and intratracheal (i.t.) dosing (7 mg/Kg) in the presence and absence of P-gp inhibitor tariquidar (TAR, 15 mg/Kg). Microdialysis was applied to determine free tissue concentration-time profiles and the obtained data were analyzed by non-compartmental and population PK (popPK) analysis. A sequential strategy was used to develop the popPK model: characterization of CIP PK in tissues (Tissue model) was performed subsequently to CIP PK modeling in plasma (Plasma model). Two and three compartmental models were used to simultaneously characterize plasma concentrations after i.t. and i.v. dosing; the distribution model was developed by separating the central compartment into venous and arterial compartment and by adding lung and prostate; TAR was identified as a significant covariate for clearance and volume of distribution of central compartment as well as for inter-compartmental clearance. Our results indicate an impact of P-gp on plasma PK, likely by acting on renal active secretion of CIP. Regarding CIP exposure in lung and prostate tissues, our results suggest a complex interplay between drug transporters; P-gp inhibition by TAR was likely counterbalanced by the activity of other efflux/influx transporters, which could not be fully characterized by our model.
Assuntos
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Próstata / Ciprofloxacina / Membro 1 da Subfamília B de Cassetes de Ligação de ATP / Pulmão / Antibacterianos / Modelos Biológicos Limite: Animals Idioma: En Revista: Eur J Pharm Sci Assunto da revista: FARMACIA / FARMACOLOGIA / QUIMICA Ano de publicação: 2019 Tipo de documento: Article País de afiliação: Brasil País de publicação: Holanda

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Próstata / Ciprofloxacina / Membro 1 da Subfamília B de Cassetes de Ligação de ATP / Pulmão / Antibacterianos / Modelos Biológicos Limite: Animals Idioma: En Revista: Eur J Pharm Sci Assunto da revista: FARMACIA / FARMACOLOGIA / QUIMICA Ano de publicação: 2019 Tipo de documento: Article País de afiliação: Brasil País de publicação: Holanda